What are the signs, risk factors, and management strategies for cefepime-induced neurotoxicity?

Cefepime Neurotoxicity: Clinical Recognition and Management

Cefepime-induced neurotoxicity (CIN) is a serious, potentially reversible complication that occurs in up to 15-23% of treated patients, particularly those with renal impairment, and requires immediate drug discontinuation when suspected. 1, 2

Clinical Manifestations

The neurological presentation of CIN is highly variable and includes:

• Altered mental status/encephalopathy (80-100% of cases) - ranging from confusion to coma
• Myoclonus (40-42%) - often a key diagnostic clue
• Reduced level of consciousness (47-80%)
• Seizures - importantly, nonconvulsive status epilepticus occurs in 25-31% of cases, far more common than convulsive seizures (11%)
• Aphasia - disturbance in speaking and understanding language
• Disorientation/agitation (47%)
• Triphasic waves on EEG (40% of those with EEG abnormalities) 3, 4, 1, 5

All patients with EEG monitoring (98 of 135 cases) showed abnormalities, making EEG a critical diagnostic tool when available 1.

Risk Factors

The primary risk factors for CIN are:

Major Risk Factors:

• Renal dysfunction (present in 80-87% of cases) - the single most important risk factor 3, 1, 5
• Advanced age (median 67-69 years) 1, 5
• Elevated cefepime concentrations - trough levels >22 mg/L with intermittent dosing or >35 mg/L with continuous infusion 3

Critical Threshold Concentrations:

According to 2019 French ICU guidelines, cefepime trough concentrations above 22 mg/L (discontinuous infusions) or steady-state concentrations above 35 mg/L (continuous infusion) are associated with neurotoxicity in 50% of patients 3. More recent data suggests no neurotoxicity occurs below 7.7 mg/L, while levels ≥38.1 mg/L always cause neurological effects 2.

Important Clinical Caveat:

CIN can occur despite appropriate renal dose adjustment in 26% of cases, meaning proper dosing does not eliminate risk 3, 1. This occurs because standard creatinine-based equations may overestimate GFR in critically ill patients, and cefepime has a relatively high pro-convulsive activity (160 times that of penicillin G) 3, 6.

Temporal Course

• Median time to symptom onset: 4 days after starting cefepime 1
• Median time to resolution: 2 days after intervention 1
• Full recovery rate: 89% of patients improve, with 87% surviving to hospital discharge 1

Management Algorithm

1. Immediate Actions When CIN Suspected:

Discontinue cefepime immediately - this is the cornerstone of management 3, 4, 1. The FDA label explicitly states to discontinue if neurotoxicity occurs 4.

2. Diagnostic Confirmation:

• Obtain therapeutic drug monitoring (TDM) if available - target trough <7.5 mg/L to prevent toxicity 2
• Perform urgent EEG to identify nonconvulsive status epilepticus or other abnormalities 1, 6
• Rule out other causes of encephalopathy (metabolic, infectious, structural)

3. Specific Interventions Based on Severity:

For mild-moderate cases:

• Drug discontinuation alone may suffice
• Monitor neurological status closely

For severe cases (seizures, status epilepticus, coma):

• Administer antiepileptic drugs as needed for seizure control 1, 7
• Consider urgent hemodialysis for:
  • Severe renal impairment preventing drug clearance
  • Life-threatening neurotoxicity
  • Failure to improve with drug cessation alone 1, 7

4. Antibiotic Substitution:

Switch to alternative antibiotics with lower neurotoxicity risk. Based on the pro-convulsive activity table, consider 3:

• Meropenem (relative activity 16 vs cefepime's 160)
• Piperacillin-tazobactam (relative activity 11)
• Ceftriaxone (relative activity 12)
• Cefotaxime (relative activity 8.8)

Prevention Strategies

In High-Risk Patients (elderly, renal dysfunction, ICU patients):

1. Implement TDM protocols - aim for trough concentrations <7.5 mg/L 2
2. Adjust doses aggressively for any degree of renal impairment, recognizing that standard equations may overestimate GFR 6
3. Consider alternative antibiotics in patients with multiple risk factors 6
4. Avoid exceeding plasma concentrations >8× MIC when possible, as benefit-risk ratio decreases 3
5. Monitor neurological status daily - any unexplained change warrants immediate evaluation 3

Common Pitfalls to Avoid:

• Attributing encephalopathy to other causes (sepsis, metabolic) without considering CIN in patients on cefepime
• Continuing cefepime while investigating other causes of altered mental status
• Failing to obtain EEG - missing nonconvulsive status epilepticus, which is more common than convulsive seizures
• Relying solely on creatinine-based dosing without TDM in high-risk patients
• Assuming appropriate dosing eliminates risk - 26% of cases occur with correct renal dosing 1

Mortality and Quality of Life Impact

In-hospital mortality is significantly higher in patients who develop CIN (35.1% vs 7.8% without neurotoxicity) 2, though this likely reflects the severity of underlying illness. The recent ACORN trial found cefepime recipients had 21% fewer delirium- and coma-free days compared to piperacillin-tazobactam 8, highlighting the substantial impact on neurological outcomes and quality of life.

The key to optimizing outcomes is early recognition and immediate discontinuation, as CIN is largely reversible when identified promptly 1, 7.